NCT04091295 2026-03-04BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of BreastAveni FoundationAvailable
NCT04566393 2026-01-28Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered MalignanciesxCuresAvailable
NCT04100694 2025-05-20Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid TumorMerus B.V.Approved for marketing
NCT03906331 2025-01-17Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) ActivationEli Lilly and CompanyApproved for marketing
NCT06751524 2024-12-30Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory ApprovalAgenus Inc.Available
NCT03554434 2020-03-02An Expanded Access Program for AM0010 (Pegilodecakin)Eli Lilly and CompanyNo longer available